Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Biomarker Research for Personalized Medicine

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2013 by Inje University.
Recruitment status was:  Recruiting
Sponsor:
Information provided by (Responsible Party):
Jae-Gook Shin, Inje University
ClinicalTrials.gov Identifier:
NCT01488591
First received: December 6, 2011
Last updated: May 30, 2013
Last verified: May 2013
  Purpose

The aim of this study :

  1. Through the study of genes of protein, transporter, translator and epigenome investigating the effect of anti-cancer treatment or the key factor of the MDR (Multidrug resistance) on the blood cancer patients who are under the anti-cancer sork treatment
  2. Giving a service of anticancer medicine therapeutic drug monitoring (TDM) and genotyping

Condition
Hematologic Neoplasms

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Biomarker Research for Personalized Medicine in Blood Cancer Patient

Further study details as provided by Inje University:

Biospecimen Retention:   Samples With DNA
whole blood

Estimated Enrollment: 1000
Study Start Date: April 2009
  Eligibility

Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
healthy volunteers
Criteria

Inclusion Criteria:

  • Korean
  • Clinical diagnosis of Hematologic neoplasms
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01488591

Locations
Korea, Republic of
Inje University
Busan, Korea, Republic of, 614-735
Sponsors and Collaborators
Inje University
  More Information

Responsible Party: Jae-Gook Shin, Department of Pharmacology and Pharmacogenomics Research Center, Inje University
ClinicalTrials.gov Identifier: NCT01488591     History of Changes
Other Study ID Numbers: 09-029 
Study First Received: December 6, 2011
Last Updated: May 30, 2013
Health Authority: Korea: Institutional Review Board

Additional relevant MeSH terms:
Hematologic Neoplasms
Neoplasms by Site
Neoplasms
Hematologic Diseases

ClinicalTrials.gov processed this record on December 09, 2016